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Glucose tolerance and plasma insulin response to intravenous 
glucose infusion and test meal in rats with microencapsulated islet 
allografts 
W. M. Fritschy l , J. H. Strubbe 2, G. H. J. Wolters 1 and R. van Schilfgaarde 1 
i DepartmentofSurgery, University of Groningen, Groningen, and 2 Department ofAnimal Physiology, University of Groningen, Haren, 
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Summary. Albino Oxford rats made diabetic with 75 mg/kg 
streptozotocin were intraperitoneally transplanted with 
2500-2900 alginate-polylysine microencapsulated Lewis is- 
lets (n = 9, total islet tissue volume 8.0-11.0 btl), or a similar 
volume of non-encapsulated L wis islets (n = 5). All rats with 
microencapsulated islets became normoglycaemic, and re- 
mained normoglycaemic for5-16 weeks. In rats with non-en- 
capsulated islet grafts, only a temporary decrease in blood 
glucose was observed, and all were again severely hypergly- 
caemic at 1 week after implantation. At 5-6 weeks after 
transplantation, glucose tolerance in rats with microencapsu- 
lated islets was tested by intravenous glucose infusion 
(10mg/min over 20min) and test meal administration 
(n = 4). During glucose infusion, maximum glucose levels 
were 13.0_+0.4mmol/1 in rats with microcapsules and 
8.9 + 0.4 mmol/1 in healthy control rats (p < 0.01). Concomi- 
tant maximum plasma insulin levels were 215 _+ 17 pmol/1 in 
rats with microcapsules and 715_+85pmol/1 in controls 
(p < 0.001). After the test meal, maximum blood glucose was 
10.6_+0.9mmol/1 in rats with microcapsules and 6.2+ 
0.1 mmol/1 in controls (p < 0.001), with concomitant maxi- 
mum plasma insulin levels of 247_+11pmol/1 and 586+ 
59 pmol/1, respectively (p < 0.001). In conclusion, although 
the glucose tolerance is impaired and plasma insulin re- 
sponses to intravenous glucose-load and test-meal are 
reduced, the alginate-polylysine membrane does provide 
adequate immunoisolation for the prolongation of allograft 
survival, resulting in prolonged normoglycaemia in strepto- 
zotocin diabetic rats. 
Key words: Glucose tolerance, streptozotocin, diabetic rats, 
microencapsulation, islet transplantation. 
The advantage of pancreatic islet transplantation over 
exogenous insulin administration i  the treatment of 
diabetes mellitus is, conceptually, the minute-to-minute 
control of glucose metabolism by an endogenous insulin 
source. It is thought hat close regulation of glucose and 
insulin levels may help to prevent long-term diabetic om- 
plications. However, after 20 years of intensive research, 
islet transplantation is still not readily available for Type 1 
(insulin-dependent) diabetic patients. The main causes 
are 1) that islet isolation techniques are inappropriate for 
obtaining large amounts of islet tissue, and 2) a lack of ap- 
propriate means to prevent graft rejection after transplan- 
tation [1-3]. 
A possible method to circumvent rejection may be im- 
muno-isolation of islets in a biocompatible membrane. 
By this technique, the encapsulated tissue is separated 
from the diabetic host by an artificial membrane which 
has to be permeable to glucose and insulin but not to 
immunologically active cells and cytotoxic antibodies [4, 
5]. In 1980, Lim and Sun described the first successful 
transplantation f rat islets microencapsulated in a cross- 
linked polyamino-acid alginate membrane [6]. Several 
other publications followed, in which it was reported that 
prolonged normoglycaemia could be achieved with algi- 
nate-polylysine microencapsulated islets after allo- [7, 8] 
or xeno-transplantation [9] in streptozotocin diabetic rats 
and mice, respectively. Recently, it has been demon- 
strated that implantation of microencapsulated islet 
grafts could also reverse hyperglycaemia in auto-immune 
diabetic rats [10] and mice [11], although the duration of 
normoglycaemia in these animal models was generally 
shorter than could be achieved in chemically induced ia- 
betic animals. However, the normalization of the plasma 
insulin levels, and in particular the capability of an intra- 
peritoneal microencapsulated islet graft to increase plas- 
ma insulin in response to blood glucose elevation has 
never been detailed. Therefore, in the present study we 
investigated blood glucose levels and plasma insulin re- 
sponses during intravenous glucose infusion and after 
test-meal administration i streptozotocin diabetic rats 
successfully transplanted with a microencapsulated islet 
allograft. 
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Materials and methods 
Animals and islet isolation 
Male rats of the highly inbred Albino Oxford strain (AO/G, weight 
280-320 g) were used as islet graft recipients. Diabetes was induced 
by intravenous injection of streptozotocin (75 mg/kg, Zanosar, agift 
from Upjohn Company, Kalamazoo, Mich., USA). Rats were dassi- 
fled as diabetic when they developed severe weight loss, polyuria, 
and non-fasting blood glucose levels exceeding 20 mmol/1 over a 
period of at least 2 weeks. 
Donor islets were isolated from highly inbred Lewis rats (Harlan 
CPB, Zeist, The Netherlands, weight 300-350 g). Under ether an- 
aesthesia, the abdomen was opened by a midline incision and the 
common bile duct was identified and cannulated. The pancreas was 
distended with 10 ml Krebs' Ringer solution containing 10% bovine 
serum albumin, excised, and cut into small pieces. A two-stage col- 
lagenase incubation at 37~ was performed with 1.2 and 0.7 mg/ml 
collagenase r spectivly (Sigma type XI, 1800 U/rag; Sigma, Chemi- 
cal Company, St. Louis, Mo., USA) [12]. The islets were separated 
from the exocrine elements by means of a 5-layer discontinuous 
dextran gradient. Subsequently, 900-1200 islets per donor pancreas 
were hand-picked, inorder to obtain a pure islet preparation. A 10% 
sample was taken for measuring the diameters of the islets and to 
calculate the total islet graft volume. All procedures were performed 
under sterile conditions and with sterilized media. 
Microencapsulation 
Immediately after isolation, the islets were encapsulated in an algi- 
nate-polylysine membrane according to a modified method of Lim 
[13] as previously published in detail [14]. Briefly, the islets were sus- 
pended in a 2.0% (weight/volume) sodium alginate solution in Ca 2 +- 
free Krebs' Ringer Hepes (Algin, lot 23814, Kelco, San Diego, 
Calif., USA, dry-sterilized with ethylene oxide). Islet-containing al- 
ginate droplets were produced with an air-jet droplet generator, and 
hardened in a 100 mmol/1 CaC12-solution. After several washes with 
Krebs' Ringer Hepes buffer (KRH, O2-gassed, pH 7.4), a polylysine 
membrane was formed by suspending the gelled alginate beads in a 
0.05% polylysine solution for 6-9 rain (poly-l-lysine-HC1, M, 22,000, 
Sigma). Subsequently, to apply the outer alginate layer, the beads 
were washed with Ca 2 § KRH and suspended ina 0.02% sodium 
alginate solution for 3-5 min. In order to liquify the inner core of the 
alginate polylysine beads, the beads were suspended in 1 mmol/1 
EGTA in Ca 2 +-free KRH for 10 rain. After three final washes in 
Ca 2+-free KRH, the microencapsulated islets were transferred to 
tissue culture Petri dishes containing RPMI culture medium, penicil- 
lin G (100 U/ml), streptomycin (100 ~tg/ml), and 10 mmol/1 glucose. 
Transplantation was performed immediately after encapsulation. 
Transplantation protocol 
A total of nine diabetic rats were transplanted with a microencapsu- 
lated islet graft, and five diabetic rats received a non-encapsulated 
islet graft. Prior to implantation, the microencapsulated islet grafts 
were carefully inspected under a stereomicroscope with side-illumi- 
nation to confirm complete ncapsulation of the islets. Each trans- 
plantation was performed with 2500-2900 islets with a calculated 
total islet tissue volume of 8.00-11.0 btl. Uniform smooth spherical 
capsules were prepared, with diameters of 800-900 btm. Each cap- 
sule contained 1-3 islets. Implantation of the microencapsulated 
islet graft into the peritoneal cavity was carried out under ether an- 
aesthesia, with a 16 gauge cannula attached to a 10 ml syringe. The 
abdomen was closed with a two-layer suture. Rats which received 
non-encapsulated allografts were implanted with 2800-3000 islets, 
with a total graft volume of 8.0--10.0 ~tl. These islets were injected 
into the peritoneal cavity through a 23 gauge butterfly needle. Non- 
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fasting blood glucose and body weight were frequently determined 
at regular intervals, as indicated in Figures 1 and 2. Blood was taken 
from the tail vein under ether anaesthesia and the glucose concentra- 
tion was determined with glucose test tapes (Reflolux, Boerhinger, 
Mannheim, FRG). Daily urine output was measured in perspex me- 
tabolic cages i week before, and 2-4 weeks after transplantation. 
Urine glucose xcretion was estimated with urine glucose test tapes 
(Glukotest, Boerhinger). 
At 4 weeks after implantation, a biopsy of the pancreas of reci- 
pient animals was taken (approximately 50 mg of the tail) to deter- 
mine whether Beta-cell regeneration had occurred. Aldehyde-fuch- 
sin positive Beta-cells in the native islets were counted and 
expressed as percentage ofthe total number of cells per islet. Before 
streptozotocin treatment, 65 % Beta-cells were present in the islets. 
Per biopsy, at least 10 islets in four different sections were evaluated. 
Cannulation surgery and glucose tolerance tests 
At 5-6 weeks after transplantation, glucose tolerance was tested by 
determining lucose and insulin levels during intravenous glucose 
infusion (IVGTT) and after test meal administration. Only normo- 
glycaemic animals, with regained body weight and less than 3% alde- 
hyde-fuchsin positive Beta-cells in their native pancreas, were pro- 
vided with two permanent intracardiac catheters, implanted via the 
right and left jugular vein into the right atrium (n = 4). These two ca- 
theters allowed blood sampling as well as intracardiac glucose infu- 
sion in unstressed, freely moving rats [15]. Normal healthy rats 
served as controls (n = 5), with an average body weight similar to 
that of the animals with encapsulated islet grafts. IVGTTs were per- 
formed by intracardiac infusion of 200 mg glucose at a rate of 
10 rag/rain. The meal tests were carried out by offering the animals 
2.0 g pelleted rat chow, after the animals had been habituated to in- 
gesting the offered meal within 5 rain [16]. To establish baseline 
values, blood samples were taken at 10 rain and immediately before 
the start of the test, and at regular intervals thereafter, as indicated in 
the figures. Each time of blood sampling, 0.3 ml blood for blood glu- 
cose and plasma insulin determination was taken from one of the 
two indwelling heart catheters. After every third blood sample, 
0.9 ml blood from a syngenic donor rat was injected into the same ca- 
theter, in order to avoid stress due to blood loss. Blood glucose con- 
centrations were determined in whole blood by a ferricyanide 
method with a Technicon autoanalyzer. Plasma insulin was 
measured by radio-immuno-assay, with rat insulin used as a stand- 
ard, as we previously described [17]. Antibody-bound insulin pre- 
cipitation was carried out with poly-ethylene-glycol [18]. 
Histological evaluation of microencapsulated islet grafts 
At 5 weeks after transplantation, microcapsules were retrieved by 
peritoneal lavage from one animal which died after cannulation 
surgery. At the same time, a biopsy was taken from the omentum to 
examine whether there were adherent microcapsules. Microcap- 
sules were also retrieved by peritoneal lavage and omental biopsies 
from the five animals which had again become hyperglycaemic at
about 1-2 weeks after the recurrence of hyperglycaemia, and from 
the three persistingly normoglycaemic animals at the time when they 
were killed (4 months after transplantation). Simultaneously, a sec- 
ond pancreas biopsy was taken from these animals to confirm the ab- 
sence or presence of native Beta-cell regeneration. Recovered cap- 
sule specimens were fixed in Bouin's olution for paraffin processing, 
and stained with aldehyde fuchsin. 
Statistical nalysis 
The Student's t-test was applied to determine significant differences 
in daily urine excretion, blood glucose and insulin levels. Values are 
given as mean _+ SEM. Differences were considered to be statisti- 
cally significant ifp < 0.05. 
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Resu l ts  
Intraperitoneal implantation of non-encapsulated islet al- 
lografts in diabetic rats (n = 5) did not reverse hypergly- 
caemia (Fig. 1). In these rats, only a temporary decrease in
blood glucose was observed, and all were again severely 
hyperglycaemic at i week after transplantation (blood 
glucose > 20 mmol/1). 
In contrast, non-fasting blood glucose levels in animals 
transplanted with microencapsulated allografts nor- 
malized in all cases (Fig. 1). The average time after which 
the animals became normoglycaemic was 7 _+ 1 days. At 
4 weeks after implantation, pancreas biopsies from native 
pancreases showed Beta-cell regeneration i three ani- 
mals (13 _+ 4% aldehyde fuchsin positive Beta-cells in the 
islets). These animals remained normoglycaemic for more 
than 4 months. One animal which died after cannulation 
surgery, had low blood glucose levels (4.0 mmol/1), and an- 
other animal became hyperglycaemic at 5 weeks after 
transplantation. The remaining four animals continued to 
be normoglycaemic for 10-14 weeks, and were subjected 
to intracardial cannulation and glucose tolerance testing. 
The normalization of body weight of animals with 
microencapsulated islet grafts corresponded well with the 
normalization of the blood glucose levels (Fig. 2). After 
streptozotocin treatment, all diabetic animals lost about 
20% of their body weight. Rats with non-encapsulated al- 
lografts howed only a short period of weight gain, where- 
as diabetic controls totally failed to gain weight. In con- 
trast, rats with microencapsulated allografts immediately 
showed body weight gain after implantation of the islets, 
which was maintained uring their normoglycaemic peri- 
od. This metabolic improvement was also demonstrated 
by a dramatic fall in urinary output from 95.5+ 
14.7 ml/24 h before to 8.2 _+ 1.6 ml/24 h after transplanta- 
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Fig.1. Non-fasting blood glucose concentrations in streptozotocin 
diabetic rats after intraperitoneal implantation of microencapsu- 
lated islet allografts (= =, n = 9), and non-encapsulated islet allo- 
grafts (~---v, n = 5). The number of animals (as indicated) decreased 
due to death, and to recurrence ofhyperglycaemia (see Results). 
GTT = glucose tolerance tests 
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Fig.2. Changes in body weight in diabetic rats after intraperitoneal 
implantation ofmicroencapsulat ed islet allografts (9 9 = 9),and 
non-encapsulated islet allografts (v--~7, n = 5); diabetic ontrol ani- 
mals (~-~, n = 6); normal healthy control animals (o--o, n = 6). 
The number of animals (as indicated) decreased due to death, and to 
recurrence of hyperglycaemia (see Results). STZ = streptozotocin, 
GTT = glucose tolerance test 
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Fig. 3. Blood glucose and plasma insulin levels after intravenous glu- 
cose infusion (10 rag/rain) in rats with intraperitoneally implanted 
microencapsulated islet allografts (= 9 n = 4), and normal healthy 
controls (O--O, n -- 5). *p < 0.05 
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Fig.4. Blood glucose and plasma insulin levels after spontaneous in- 
gestion of a test meal in rats with intraperitoneally implanted micro- 
encapsulated islet allografts (~--e, n = 4), and in normal healthy 
control animals (o--<), n = 5). *p < 0.05 
pletely eliminated, since it was _> 28 mmol/1 before and 
0-2.2 retool/1 after transplantation. 
Prior to the glucose tolerance tests, basal glucose levels 
in rats with microencapsulated islets were somewhat 
higher than in normal control animals (p < 0.05), which 
corresponded with the concomitant basal plasma insulin 
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levels, since these were found to be lower in rats with 
microencapsulated islets than in normal controls (Figs. 3 
and 4). Maximum blood glucose levels were significantly 
higher in rats with microencapsulated islets than in nor- 
mal control rats, both during glucose infusion (13.0 + 0.4 
and 8.9 _+ 0.4 mmol/1, respectively, p < 0.01) and after test 
meal administration (10.6 _+ 0.9 and 6.2 +_ 0.1 mmol/1, re- 
spectively, p < 0.001). This is in accordance with the con- 
comitant plasma insulin, which showed hardly any in- 
crease in rats with microcapsules, whereas normal control 
animals howed a considerable plasma insulin elevation 
with both test situations. 
On histological examination, microcapsules retrieved 
by peritoneal lavage from the animal which died after can- 
nulation surgery (5 weeks after transplantation) were 
found to contain viable islets with aldehyde-fuchsin posi- 
tive Beta-cells (Fig. 5 a). These microcapsules were intact 
and largely free from cellular overgrowth. However, when 
the omentum of this animal was histologically examined, 
other microcapsules were found to be adherent to the 
omentum and overgrown with fibrous tissue (Fig.5b). 
These capsules, which could not be flushed out by perito- 
neal lavage, contained non-viable islet remnants. 
Histological examination of microcapsules retrieved 
from animals which had again become hyperglycaemic 
showed many capsules overgrown with fibrotic tissue and 
few capsules free from cellular overgrowth. In these ani- 
mals, neither capsules with fibrotic overgrowth, nor cap- 
sules free from cellular overgrowth contained viable islet 
tissue. In contrast, capsules retrieved from animals still 
ormoglycaemic at the time of peritoneal lavage, con- 
tained viable aldehyde-fuchsin positive Beta-cells, though 
only when the capsule surface was free from cellular over- 
growth. 
The histological appearance of the pancreases at the 
end of the study confirmed the observations of the pre- 
viously taken pancreas biospies. Hyperglycaemic reci- 
pients showed no aldehyde fuchsin positive Beta-cells, 
whereas the animals with persistent normoglycaemia 
showed considerable Beta cell regeneration, although to a 
lesser extent han in their first pancreas biopsy (8.5 + 2% 
aldehyde fuchsin positive Beta-cells in the islets). 
Fig.5 a,b. Alginate polylysine 
microencapsulated rat islets recovered from 
the peritoneal cavity at 5 weeks after 
allo-transplantation, a Aldehyde fuchsin, 
100 x, b Microcapsules in omental fat 
tissue, aldehyde fuchsin, 200 x 
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Discussion 
The present study shows that normoglycaemia c n be 
achieved after transplantation f microencapsulated rat is- 
let allografls into streptozotocin diabetic recipients, in the 
absence of immunosuppressive therapy. These results 
thereby confirm other studies on islet microencapsulation 
[6-8,10]. We found that implantation of non-encapsulated 
islets led to only a temporary decrease of blood glucose 
levels, followed by a quick return to hyperglycaemia. It is 
likely that these islets were subject o allograft rejection, 
which demonstrates the immunoprotective properties of 
the alginate-polylysine membrane in case of the encap- 
sulated islet graft. These immunoprotective properties 
were further substantiated bythe retrieval of histologically 
viable and intact islets within microcapsules from normo- 
glycaemic recipients. However, our study also extends pre- 
vious observations by demonstrating that, in spite of per- 
sisting normoglycaemia, the kinetic responses to oral and 
intravenous glucose challenge were far from normal. 
Spontaneous Beta-cell regeneration i the host native 
pancreas may occur after induction of diabetes with strep- 
tozotocin [19-21]. Indeed, at 1 month after transplanta- 
tion we found a considerable number of aldehyde-fuchsin 
positive Beta-cells in the native pancreases in three out of 
nine recipients. A similar observation was made by Chi- 
cheportiche et al. [22], who found extensive regeneration 
in the recipient pancreas after implantation of microen- 
capsulated islet xenografts. Since we could not rule out a 
contribution of regenerated native Beta cells to the pro- 
longed normoglycaemia, these three animals were not 
subjected to further evluation by glucose tolerance test- 
ing. The normoglycaemia observed in the other animals 
could not be attributed to native Beta-cell regeneration, 
since this was histologically excluded. 
These animals howed that the microencapsulated islet 
allograft was quite effective in restoring normoglycaemia 
and sufficiently adequate to normalize both weight gain 
and body weight as well as the volume of urine output. 
This is in contrast to a previous tudy in which it was dem- 
onstrated that the increase of body weight is only limited 
to the first few weeks following transplantation [10]. The 
low insulin increments during glucose tolerance testing 
seem to indicate that the observed non-fasting normogly- 
caemia was achieved by only basal release of insulin from 
the encapsulated islet graft. A similar effect on blood glu- 
cose in streptozotocin diabetic rats can be obtained by the 
implantation of insulin containing polymer matrices [23- 
25]; devices which release insulin at a basal rate without 
any response to blood glucose levation. However, there 
is a principal difference in kinetic performance since we 
demonstrated in a previous tudy that glycaemic stimula- 
tion of microencapsulated islets results in a rapid and sig- 
nificant insulin response when tested in vitro [14]. Thus, 
other factors hould be considered to explain for the lack 
of insulin response by microencapsulated islets after 
transplantation. 
One factor is that unfavourable glucose and insulin dif- 
fusion kinetics over the membrane may have contributed 
to the reduced insulin responses, ince we used slightly 
larger microcapsules in this study than in our previous in 
vitro experiments [26]. This effect may have been further 
enhanced by the fact that the majority of rat islets, isolated 
from one donor pancreas, have small diameters [27] and 
consequently relativily large capsules. 
A second factor to consider is the total volume of the 
grafted islet tissue in relation to the transplantation site. In 
a recent study, we demonstrated that intraperitoneal im- 
plantation of free isogenic islets with a total islet tissue vol- 
ume of 8.0-10.0 gl normalizes blood glucose levels in 
diabetic rats routinely, and restores adequate glucose me- 
tabolism and insulin responses during IVGTT and test 
meal [28]. However, the principal difference between free 
and microencapsulated islet grafts is that free islets 
become attached to the abdominal viscera and become 
completely vascularized, while microcapsules freely float 
across the peritoneal cavity, without any vascular access. 
This implies that a delay of glucose and insulin exchange 
between the peritoneal f uid and the blood may have con- 
sequences for the magnitude and the rapidity of the plas- 
ma insulin response. For instance, it has been demon- 
strated that the intraperitoneal g ucose concentration i
rats follows the blood glucose with a 5 rain delay [291. On 
the other hand, also the rate of absorption of intraperito- 
neally delivered insulin into the circulation was found to 
be time-dependent [30], and directly related to the se- 
creted amount of insulin [31]. Whether the amount of in- 
sulin, maximally secreted by 8.0-11.0 btl encapsulated islet 
tissue, is sufficient o induce an adequate plasma insulin 
response isquestionable [14, 32, 33], and has to be further 
investigated. 
A final factor relating to the impaired glucose toler- 
ance may be a gradual decrease of the number of viable 
and functioning islets after transplantation. Some obser- 
vations ubstantiate his hypothesis. First, at 5 weeks after 
implantation many islet-containing capsules could be re- 
trieved with peritoneal lavage, but it was also found that 
some capsules were attached to the omentum, surrounded 
by a fibrotic reaction and containing non-viable islet rem- 
nants. Second, all animals that had been normoglycaemic 
in the absence of native Beta-cell regeneration successive- 
ly returned to hyperglycaemia n the course of 5 to 
14 weeks. From these animals no viable islets could be re- 
trieved. Finally, peritoneal lavage in animals which had 
maintained prolonged normoglycaemia in the presence of 
native Beta-cell regeneration yielded only few islet-con- 
taining capsules free fi'om cellular overgrowth. 
The main reason for the gradual oss of islet function 
seems to be the occurrence of fibrotic overgrowth, im- 
peding the diffusion of hormones and metabolites 
through the capsule membrane. An additional mecha- 
nism may well be that, as a consequence of gradual loss of 
islet mass, the remaining islets within the non-overgrown 
capsules are subject o exhaustion and ultimate decrease 
of viability. 
In conclusion, our data show that implantation of 
microencapsulated islets effectively restores normogly- 
caemia, urine output, and weight gain in streptozotocin 
diabetic rats for up to 4 months, and that the alginate- 
polylysine membrane can provide adequate immunoiso- 
lation after transplantation. However, we found that, 
despite the major metabolic improvement, glucose 
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to lerance remained severely impaired,  because the encap- 
sulated islet graft was not able to increase p lasma insulin 
levels adequate ly  in response to b lood glucose elevation. 
Re levant  factors in this regard are the size of the micro- 
capsules appl ied,  the total  vo lume of the encapsulated 
islet tissue, and a gradual  decrease in graft viability. 
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